1. Bioorg Med Chem. 2006 May 15;14(10):3307-19. doi: 10.1016/j.bmc.2005.12.052. 
Epub 2006 Jan 24.

Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable 
melanin-concentrating hormone receptor 1 antagonists.

Kanuma K(1), Omodera K, Nishiguchi M, Funakoshi T, Chaki S, Nagase Y, Iida I, 
Yamaguchi J, Semple G, Tran TA, Sekiguchi Y.

Author information:
(1)Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd, 1-403 
Yoshino-cho, Kita-ku, Saitama, Saitama 331-9530, Japan.

The optimization of the distance between two key pharmacophore features within 
our first hit compounds 1a and 2a led to the identification of a new class of 
potent non-peptidic antagonists for the MCH-R1, based around 
4-amino-2-cyclohexylaminoquinazolines. In particular, ATC0065 (2c), 
N2-[cis-4-([2-[4-Bromo-2-(trifluoromethoxy)phenyl]ethyl]amino)cyclohexyl]-N4,N4-dimethylquinazoline-2,4-diamine 
dihydrochloride, bound with high affinity to the MCH-R1 (IC50 value of 16 nM) 
and showed good metabolic stability in liver microsomes from human and rat.

DOI: 10.1016/j.bmc.2005.12.052
PMID: 16434202 [Indexed for MEDLINE]
